Results 131 to 140 of about 9,527 (221)

Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study

, 2022
Tatsuya Maruhashi, Yukihito Higashi, Hisako Yoshida, Atsushi Tanaka, Katsumi Eguchi, Hirofumi Tomiyama, Kazuomi Kario, Toru Kato, Nozomu Oda, Nobuhiro Tahara, Mitsutoshi Oguri, Hirotaka Watada, Koichi Node   +12 more
openalex   +1 more source

Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial [PDF]

, 2022
Byeongzu Ghang, Ji Sung Lee, Jihye Choi, Jinseok Kim, Bin Yoo   +4 more
openalex   +1 more source

Investigation and Physicochemical Characterization of Binary Febuxostat- Sulfobutyl Ether β -Cyclodextrin Inclusion Complexes [PDF]

, 2022
Wedad Sakran, Rania Safa, Mai Abdel-Hakim, Mohamed Salah   +3 more
openalex   +1 more source

Febuxostat Improves MASLD in Male Rats: Roles of XOR Inhibition and Associated JNK/NRF2/HO-1 Pathway Changes. [PDF]

Int J Mol Sci
Pu Z, Cen Y, Yang B, Xing K, Lian L, Chi X, Yang J, Zhang Y.   +7 more
europepmc   +1 more source

Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal

, 2009
Matt Stevenson, Abdullah Pandor
openalex   +2 more sources

Hepatic Safety of Febuxostat and Allopurinol in Gout Patients: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Ther Clin Risk Manag
Dewi C, Puspita F, Insani WN, Sinuraya RK, Puspitasari IM, Zakiyah N.   +5 more
europepmc   +1 more source

Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice [PDF]

, 2014
Johji Nomura, Nathalie Busso, Annette Ives, Chieko Matsui, Syunsuke Tsujimoto, Takashi Shirakura, Mizuho Tamura, Tsunefumi Kobayashi, Alexander So, Yoshihiro Yamanaka   +9 more
openalex   +1 more source

Efficacy and safety of urate-lowering therapies in asymptomatic hyperuricaemia: a systematic review and network meta-analysis of key clinical outcomes. [PDF]

Ann Med
Yi Y, Yang J, Chen Y, Liu H, Deng Y.
europepmc   +1 more source

Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations [PDF]

, 2017
Hiroshi Miyata, Hiroshi Suzuki, Hirotaka Matsuo, Kimiyoshi Ichida, Tappei Takada, Yu Toyoda   +5 more
core   +1 more source

Supplementary Material for: Febuxostat Prevents Renal Interstitial Fibrosis by the Activation of BMP-7 Signaling and Inhibition of USAG-1 Expression in Rats

, 2015
Jun Cao, Yingchun Li, Peng Yan-shen, Y. Zhang, H. Li, Ruiyin Li, A. Xia   +6 more
openalex   +1 more source